LMT
45
-4
SYK
59
-5
BAC
41
5
TRIP
57
5
ECL
72
-2
DFS
56
2
AVGO
40
-24
AIV
62
-3
TMO
58
-2
URI
59
6
CAH
54
-4
AZO
45
-3
WM
62
-6
MMM
50
-2
R
67
4
CME
59
-2
GOOG
61
2
NWL
35
-5
MU
28
2
FAST
48
2
LMT
45
-4
SYK
59
-5
BAC
41
5
TRIP
57
5
ECL
72
-2
DFS
56
2
AVGO
40
-24
AIV
62
-3
TMO
58
-2
URI
59
6
CAH
54
-4
AZO
45
-3
WM
62
-6
MMM
50
-2
R
67
4
CME
59
-2
GOOG
61
2
NWL
35
-5
MU
28
2
FAST
48
2
Financhill
Back

Syros Pharmaceuticals 10K Form

Sell
38

SYRS
Syros Pharmaceuticals

Last Price:
2.01
Seasonality Move:
-18.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SYRS News And Ratings

See the #1 stock for the next 7 days that we like better than SYRS

SYRS Financial Statistics

Sales & Book Value

Annual Sales: $9.94M
Cash Flow: $-29.67M
Price / Cash Flow: 0
Annual Sales: $-0.24
Price / Book: 0

Profitability

EPS (TTM): -4.34000
Net Income (TTM): $-131.56M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Syros Pharmaceuticals Earnings Forecast

Key Syros Pharmaceuticals Financial Ratios

  • The Research & Development expenses have been 1,088.50% of Revenue.
  • The Interest Expense is -3.12% of Operating Income.
  • The Net Earning history of SYRS is -1,656.34% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 8 years.

Syros Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SYRS
CUSIP: 87184Q
Website: syros.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SYRS Technical Analysis vs Fundamental Analysis

Sell
38
Syros Pharmaceuticals (SYRS) is a Sell

Is Syros Pharmaceuticals a Buy or a Sell?